<DOC>
	<DOCNO>NCT02544750</DOCNO>
	<brief_summary>This trial consist 2 part : double-blinded phase open-label extension phase . The open-label extension phase describe record . All participant receive dose GWP42003-P . However , investigator may subsequently decrease increase participant 's dose optimal dose find .</brief_summary>
	<brief_title>An Open-label Extension Trial Cannabidiol ( GWP42003-P , CBD ) Seizures Tuberous Sclerosis Complex ( GWPCARE6 )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<criteria>Key Completion GWEP1521 Blinded Phase</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>